Teva Pharmaceutical (TEVA) Price & Analysis

Compare

7,502 Followers

TEVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$12.47 - $22.80

Previous CloseN/A

Volume1.13M

Average Volume (3M)10.48M

Market Cap

$21.65B

Enterprise Value$34.83B

Total Cash (Recent Filing)$2.16B

Total Debt (Recent Filing)$17.52B

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Nov 05, 2025

EPS Estimate

0.67

Last Dividend Ex-Date

Nov 27, 2017

Dividend YieldN/A

Share Statistics

EPS (TTM)0.66

Shares Outstanding1,146,838,700

10 Day Avg. Volume10,762,087

30 Day Avg. Volume10,476,089

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.61

Enterprise Value/Revenue2.09

Enterprise Value/Gross Profit4.22

Enterprise Value/Ebitda18.35

Forecast

1Y Price Target

$24.00

Price Target Upside25.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Credit Rating And Cash FlowManagement’s confidence in achieving an IG rating by 2H26 irrespective of outcome of TAPI divestiture.

Market Positioning And ValuationTEVA is well-positioned for upside with shares trading at less than 7 times the 2025 estimated earnings per share and increasing capital allocation flexibility.

Product Growth And GuidanceKey US brands Uzedy, Austedo, and Ajovy saw FY25 guidance raise of ~$100m, indicating strong growth potential.

Bears Say

Generic Drug PerformanceUS generics missed forecast, mainly due to lower g-Revlimid contribution.

Stock OverhangPending Austedo IRA pricing outcome has been a major stock overhang.

Teva Pharmaceutical News

Teva put volume heavy and directionally bearish

Bearish flow noted in Teva (TEVA) with 18,300 puts trading, or 6x expected. Most active are 9/26 weekly...

6d ago

TEVA

Teva price target raised to $26 from $23 at UBS

UBS raised the firm’s price target on Teva (TEVA) to $26 from $23 and keeps a Buy rating...

7d ago

TEVA

Teva announces presentation of data from survey of patients taking AUSTEDO XR

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of data from a real-world...

10d ago

TEVA

Teva preesents 10 posters from its schizophrenia medicines portfolio

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of 10 posters from its...

10d ago

TEVA

Teva’s emrusolmin granted U.S. FDA Fast Track designation

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the U.S. Food and Drug Administration,...

22d ago

TEVA

Teva Pharmaceutical: Strategic Focus and Financial Stability Drive Buy Rating

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Teva Pharmaceutical. The associated...

6d ago

TEVA

Riot, D-Wave, AmEx, Lowe’s, Teva: Stock Shake-Up!

Insiders have been trading these 5 stocks: (($RIOT)), (($QBTS)), (($AXP)), (($LOW)) and (($TEVA)). Here is a breakdown of...

18d ago

AXP

LOW

Teva announces FDA approval, launch of Generic Saxenda

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the FDA approval and U.S. launch of...

1M ago

TEVA

Acadia Pharmaceuticals names Katcheves Chief Business and Strategy Officer

Acadia Pharmaceuticals (ACAD) announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy...

1M ago

ACAD

TEVA

Teva put volume heavy and directionally bearish

Bearish flow noted in Teva (TEVA) with 22,082 puts trading, or 5x expected. Most active are 8/22 weekly...

1M ago

TEVA

GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks

The famed investor doubled down on his airline stock holdings. ...

1M ago

BAC

DAL

Teva announces U.S. FDA has approved AJOVY for preventive treatment

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the U.S. Food and Drug Administration,...

2M ago

TEVA

Teva Pharmaceuticals Reports Improved Earnings Amid Strategic Focus

Teva Pharmaceutical Industries Limited ( ($TEVA) ) has released its Q2 earnings. Here is a breakdown of the...

2M ago

TEVA

Teva’s Earnings Call Highlights Strong Innovative Growth

Teva Pharmaceutical Industries Limited (($TEVA)) has held its Q2 earnings call. Read on for the main highlights of...

2M ago

TEVA

TEVA FAQ

What was Teva Pharmaceutical’s price range in the past 12 months?

Teva Pharmaceutical lowest stock price was $12.46 and its highest was $22.80 in the past 12 months.

What is Teva Pharmaceutical’s market cap?

Teva Pharmaceutical’s market cap is $21.65B.

When is Teva Pharmaceutical’s upcoming earnings report date?

Teva Pharmaceutical’s upcoming earnings report date is Nov 05, 2025 which is in 35 days.

How were Teva Pharmaceutical’s earnings last quarter?

Teva Pharmaceutical released its earnings results on Jul 30, 2025. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.617 by $0.043.

Is Teva Pharmaceutical overvalued?

According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Teva Pharmaceutical pay dividends?

Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here

What is Teva Pharmaceutical’s EPS estimate?

Teva Pharmaceutical’s EPS estimate is 0.67.

How many shares outstanding does Teva Pharmaceutical have?

Teva Pharmaceutical has 1,146,838,700 shares outstanding.

What happened to Teva Pharmaceutical’s price movement after its last earnings report?

Teva Pharmaceutical reported an EPS of $0.66 in its last earnings report, beating expectations of $0.617. Following the earnings report the stock price went up 1.753%.

Which hedge fund is a major shareholder of Teva Pharmaceutical?

Currently, no hedge funds are holding shares in TEVA

Teva Pharmaceutical Stock Smart Score

Outperform

Fundamentals

Return on Equity

-2.31%

Trailing 12-Months

Asset Growth

-2.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva Pharmaceutical (TEVA) Earnings & Revenues

Historic Earnings Reports

TEVA Company Deck

TEVA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment driven by strong growth in the innovative portfolio and strategic advancements in the pipeline, despite challenges in the generics market and uncertainties regarding tariffs.View all TEVA earnings summaries

TEVA Revenue Breakdown

54.45% North America

32.42% Europe

13.12% International Markets

TEVA Stock 12 Month Forecast

Average Price Target

$24.00

▲(25.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","18":"$18","22":"$22","26":"$26","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18,22,26,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.75,19.53846153846154,20.326923076923077,21.115384615384617,21.903846153846153,22.692307692307693,23.48076923076923,24.26923076923077,25.057692307692307,25.846153846153847,26.634615384615383,27.423076923076923,28.21153846153846,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.75,19.153846153846153,19.557692307692307,19.96153846153846,20.365384615384617,20.76923076923077,21.173076923076923,21.576923076923077,21.98076923076923,22.384615384615383,22.78846153846154,23.192307692307693,23.596153846153847,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.75,18.76923076923077,18.78846153846154,18.807692307692307,18.826923076923077,18.846153846153847,18.865384615384617,18.884615384615383,18.903846153846153,18.923076923076923,18.942307692307693,18.96153846153846,18.98076923076923,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >